Summary:
Learn More About Clinical Trials
for mild cognitive impairment due to Alzheimer’s disease
The ASCENT clinical trials are evaluating an investigational drug called PRX012 in adults ages 55 to 85 with a confirmed or suspected diagnosis of mild Alzheimer’s disease or mild cognitive impairment due to Alzheimer’s disease. The investigational drug, PRX012, is designed to target, and potentially clear amyloid plaques (abnormal clumps) found in the brains of people with Alzheimer’s disease. The direct link between amyloid reduction and improvement in memory loss has not been established but is being further explored.
The investigational study drug will be given as an injection into the upper arm of the individual, just under the skin. This is called a subcutaneous injection (SC) injection. The ASCENT-1 clinical trial is expected to last approximately 6 months and includes 9 study visits. The ASCENT-2 clinical trial is expected to last approximately 1 year and includes up to 23 visits. Participants in each trial will be placed by chance into a clinical trial treatment group to receive the investigational drug, PRX012 or placebo. A placebo has no active ingredient and is used to compare the effects of the investigational drug. The placebo will look like the investigational drug and will be administered the same way but has no active ingredients.
You or your loved one may qualify if you or they:
- Are 55 to 85 years old
- Have a confirmed or suspected diagnosis of mild Alzheimer’s disease or mild cognitive impairment due to Alzheimer’s disease
- Gradual and progressive change in memory function for at least 6 months
- Willing and able to complete brain imaging (MRI and PET Scans)
There are additional clinical trial requirements to participate. A clinical trial representative will discuss them with you during the screening period.